{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T13:50:12Z","timestamp":1787320212887,"version":"build-2736575974"},"reference-count":99,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T00:00:00Z","timestamp":1716249600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T00:00:00Z","timestamp":1716249600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Zewail City of Science & Technology"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Hepatocellular carcinoma (HCC) causes significant cancer mortality worldwide. Cancer organoids can serve as useful disease models by high costs, complexity, and contamination risks from animal-derived products and extracellular matrix (ECM) that limit its applications. On the other hand, synthetic ECM alternatives also have limitations in mimicking native biocomplexity. This study explores the development of a physiologically relevant HCC organoid model using plasma-derived extracellular matrix as a scaffold and nutritive biomatrix with different cellularity components to better mimic the heterogenous HCC microenvironment. Plasma-rich platelet is recognized for its elevated levels of growth factors, which can promote cell proliferation. By employing it as a biomatrix for organoid culture there is a potential to enhance the quality and functionality of organoid models for diverse applications in biomedical research and regenerative medicine and to better replicate the heterogeneous microenvironment of HCC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>To generate the liver cancer organoids, HUH-7 hepatoma cells were cultured alone (homogenous model) or with human bone marrow-derived mesenchymal stromal cells and human umbilical vein endothelial cells (heterogeneous model) in plasma-rich platelet extracellular matrix (ECM). The organoids were grown for 14 days and analyzed for cancer properties including cell viability, invasion, stemness, and drug resistance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>HCC organoids were developed comprising HUH-7 hepatoma cells with or without human mesenchymal stromal and endothelial cells in plasma ECM scaffolds. Both homogeneous (HUH-7 only) and heterogeneous (mixed cellularity) organoids displayed viability, cancer hallmarks, and chemoresistance. The heterogeneous organoids showed enhanced invasion potential, cancer stem cell populations, and late-stage HCC genetic signatures versus homogeneous counterparts.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The engineered HCC organoids system offers a clinically relevant and cost-effective model to study liver cancer pathogenesis, stromal interactions, and drug resistance. The plasma ECM-based culture technique could enable standardized and reproducible HCC modeling. It could also provide a promising option for organoid culture and scaling up.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12967-024-05230-7","type":"journal-article","created":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T17:01:21Z","timestamp":1716310881000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Plasma-derived extracellular matrix for xenofree and cost-effective organoid modeling for hepatocellular carcinoma"],"prefix":"10.1186","volume":"22","author":[{"given":"Azza M.","family":"El-Derby","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mennatallah A.","family":"Khedr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nehal I.","family":"Ghoneim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud M.","family":"Gabr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherry M.","family":"Khater","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-3999-4898","authenticated-orcid":false,"given":"Nagwa","family":"El-Badri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,21]]},"reference":[{"issue":"3","key":"5230_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"Cancer J Clin"},{"issue":"1","key":"5230_CR2","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41572-020-00240-3","volume":"7","author":"JM Llovet","year":"2021","unstructured":"Llovet JM, et al. Hepatocellular carcinoma. Nat Reviews Disease Primers. 2021;7(1):6.","journal-title":"Nat Reviews Disease Primers"},{"key":"5230_CR3","unstructured":"Sevic I, et al. The role of the tumor microenvironment in the development and progression of hepatocellular carcinoma. Exon; 2019. pp. 29\u201345."},{"issue":"1","key":"5230_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13045-019-0782-x","volume":"12","author":"Z Yin","year":"2019","unstructured":"Yin Z, et al. Heterogeneity of cancer-associated fibroblasts and roles in the progression, prognosis, and therapy of hepatocellular carcinoma. J Hematol Oncol. 2019;12(1):1\u20139.","journal-title":"J Hematol Oncol"},{"issue":"2","key":"5230_CR5","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.canlet.2015.07.018","volume":"379","author":"L Li","year":"2016","unstructured":"Li L, Wang H. Heterogeneity of liver cancer and personalized therapy. Cancer Lett. 2016;379(2):191\u20137.","journal-title":"Cancer Lett"},{"issue":"4","key":"5230_CR6","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1007\/s40610-017-0073-7","volume":"3","author":"F Runa","year":"2017","unstructured":"Runa F, et al. Tumor microenvironment heterogeneity: challenges and opportunities. Curr Mol Biology Rep. 2017;3(4):218\u201329.","journal-title":"Curr Mol Biology Rep"},{"key":"5230_CR7","doi-asserted-by":"publisher","first-page":"p501","DOI":"10.1007\/s11626-999-0060-2","volume":"35","author":"VI Khaoustov","year":"1999","unstructured":"Khaoustov VI, et al. Induction of three-dimensional assembly of human liver cells by simulated microgravity. Vitro Cell Dev Biology-Animal. 1999;35:p501\u2013509.","journal-title":"Vitro Cell Dev Biology-Animal"},{"key":"5230_CR8","unstructured":"He C et al. Liver Organoids, Novel and Promising modalities for Exploring and Repairing Liver Injury. Stem Cell Reviews Rep, 2022: p. 1\u201313."},{"key":"5230_CR9","doi-asserted-by":"crossref","unstructured":"Tharehalli U, Svinarenko M, Lechel A. Remodelling and improvements in organoid technology to study liver carcinogenesis in a dish Stem cells international, 2019. 2019.","DOI":"10.1155\/2019\/3831213"},{"issue":"6","key":"5230_CR10","doi-asserted-by":"publisher","first-page":"2100094","DOI":"10.1002\/gch2.202100094","volume":"6","author":"H Tian","year":"2022","unstructured":"Tian H, et al. Biophysics role and Biomimetic Culture systems of ECM stiffness in Cancer EMT. Global Challenges. 2022;6(6):2100094.","journal-title":"Global Challenges"},{"issue":"1","key":"5230_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0014-4827(92)90397-Q","volume":"202","author":"S Vukicevic","year":"1992","unstructured":"Vukicevic S, et al. Identification of multiple active growth factors in basement membrane Matrigel suggests caution in interpretation of cellular activity related to extracellular matrix components. Exp Cell Res. 1992;202(1):1\u20138.","journal-title":"Exp Cell Res"},{"key":"5230_CR12","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1007\/s10616-014-9727-y","volume":"67","author":"NC Talbot","year":"2015","unstructured":"Talbot NC, Caperna TJ. Proteome array identification of bioactive soluble proteins\/peptides in Matrigel: relevance to stem cell responses. Cytotechnology. 2015;67:873\u201383.","journal-title":"Cytotechnology"},{"issue":"1","key":"5230_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-022-11641-7","volume":"12","author":"A Al Hrout","year":"2022","unstructured":"Al Hrout A, et al. Modelling liver cancer microenvironment using a novel 3D culture system. Sci Rep. 2022;12(1):1\u201314.","journal-title":"Sci Rep"},{"issue":"1","key":"5230_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-020-17161-0","volume":"11","author":"G Sorrentino","year":"2020","unstructured":"Sorrentino G, et al. Mechano-modulatory synthetic niches for liver organoid derivation. Nat Commun. 2020;11(1):1\u201310.","journal-title":"Nat Commun"},{"issue":"7","key":"5230_CR15","doi-asserted-by":"publisher","first-page":"0096","DOI":"10.1038\/s41551-017-0096","volume":"1","author":"EH Nguyen","year":"2017","unstructured":"Nguyen EH, et al. Versatile synthetic alternatives to Matrigel for vascular toxicity screening and stem cell expansion. Nat Biomedical Eng. 2017;1(7):0096.","journal-title":"Nat Biomedical Eng"},{"issue":"2","key":"5230_CR16","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.blre.2013.02.001","volume":"27","author":"T Burnouf","year":"2013","unstructured":"Burnouf T, et al. Blood-derived biomaterials and platelet growth factors in regenerative medicine. Blood Rev. 2013;27(2):77\u201389.","journal-title":"Blood Rev"},{"key":"5230_CR17","doi-asserted-by":"crossref","unstructured":"Song R et al. Current development of biodegradable polymeric materials for biomedical applications Drug design, development and therapy, 2018: pp. 3117\u20133145.","DOI":"10.2147\/DDDT.S165440"},{"key":"5230_CR18","doi-asserted-by":"crossref","unstructured":"Spotnitz WD. Fibrin sealant: the only approved hemostat, sealant, and adhesive\u2014a laboratory and clinical perspective International Scholarly Research Notices, 2014. 2014.","DOI":"10.1155\/2014\/203943"},{"key":"5230_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/scrt218","volume":"4","author":"PR Amable","year":"2013","unstructured":"Amable PR, et al. Platelet-rich plasma preparation for regenerative medicine: optimization and quantification of cytokines and growth factors. Stem Cell Res Ther. 2013;4:1\u201313.","journal-title":"Stem Cell Res Ther"},{"key":"5230_CR20","doi-asserted-by":"publisher","first-page":"99","DOI":"10.3389\/fbioe.2018.00099","volume":"6","author":"M Weber","year":"2018","unstructured":"Weber M, et al. Blood-contacting biomaterials: in vitro evaluation of the hemocompatibility. Front Bioeng Biotechnol. 2018;6:99.","journal-title":"Front Bioeng Biotechnol"},{"issue":"1","key":"5230_CR21","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1111\/j.1751-2824.2009.01222.x","volume":"4","author":"T Burnouf","year":"2009","unstructured":"Burnouf T, et al. Blood-derived biomaterials: fibrin sealant, platelet gel and platelet fibrin glue. ISBT Sci Ser. 2009;4(1):136\u201342.","journal-title":"ISBT Sci Ser"},{"issue":"1","key":"5230_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12943-016-0572-9","volume":"16","author":"K Nio","year":"2017","unstructured":"Nio K, Yamashita T, Kaneko S. The evolving concept of liver cancer stem cells. Mol Cancer. 2017;16(1):1\u201312.","journal-title":"Mol Cancer"},{"issue":"2","key":"5230_CR23","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.jhep.2009.10.026","volume":"52","author":"B Terris","year":"2010","unstructured":"Terris B, Cavard C, Perret C. EpCAM, a new marker for cancer stem cells in hepatocellular carcinoma. J Hepatol. 2010;52(2):280\u20131.","journal-title":"J Hepatol"},{"issue":"17","key":"5230_CR24","doi-asserted-by":"publisher","first-page":"5069","DOI":"10.7150\/jca.44697","volume":"11","author":"J-Y Zhuo","year":"2020","unstructured":"Zhuo J-Y, et al. CK19-positive hepatocellular carcinoma is a characteristic subtype. J Cancer. 2020;11(17):5069.","journal-title":"J Cancer"},{"issue":"10","key":"5230_CR25","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1111\/j.1349-7006.2003.tb01366.x","volume":"94","author":"T Uenishi","year":"2003","unstructured":"Uenishi T, et al. Cytokeratin 19 expression in hepatocellular carcinoma predicts early postoperative recurrence. Cancer Sci. 2003;94(10):851\u20137.","journal-title":"Cancer Sci"},{"issue":"20","key":"5230_CR26","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1093\/jnci\/dji315","volume":"97","author":"W Yeo","year":"2005","unstructured":"Yeo W, et al. A randomized phase III study of doxorubicin versus cisplatin\/interferon \u03b1-2b\/doxorubicin\/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. J Natl Cancer Inst. 2005;97(20):1532\u20138.","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"5230_CR27","doi-asserted-by":"publisher","first-page":"2886","DOI":"10.1038\/s41598-018-21200-8","volume":"8","author":"AR Mazzocchi","year":"2018","unstructured":"Mazzocchi AR, et al. In vitro patient-derived 3D mesothelioma tumor organoids facilitate patient-centric therapeutic screening. Sci Rep. 2018;8(1):2886.","journal-title":"Sci Rep"},{"issue":"3","key":"5230_CR28","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1002\/1097-0142(19880801)62:3<479::AID-CNCR2820620306>3.0.CO;2-L","volume":"62","author":"CL Lai","year":"1988","unstructured":"Lai CL, et al. Doxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma. A prospective randomized trial. Cancer. 1988;62(3):479\u201383.","journal-title":"Cancer"},{"issue":"19","key":"5230_CR29","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1001\/jama.2010.1672","volume":"304","author":"GK Abou-Alfa","year":"2010","unstructured":"Abou-Alfa GK, et al. Doxorubicin plus Sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial. JAMA. 2010;304(19):2154\u201360.","journal-title":"JAMA"},{"issue":"3","key":"5230_CR30","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1111\/jphp.12869","volume":"70","author":"M Baxter-Holland","year":"2018","unstructured":"Baxter-Holland M, Dass CR. Doxorubicin, mesenchymal stem cell toxicity and antitumour activity: implications for clinical use. J Pharm Pharmacol. 2018;70(3):320\u20137.","journal-title":"J Pharm Pharmacol"},{"issue":"12","key":"5230_CR31","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1038\/sj.onc.1210811","volume":"27","author":"S Ma","year":"2008","unstructured":"Ma S, et al. CD133\u2009+\u2009HCC cancer stem cells confer chemoresistance by preferential expression of the Akt\/PKB survival pathway. Oncogene. 2008;27(12):1749\u201358.","journal-title":"Oncogene"},{"issue":"1","key":"5230_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12885-019-5838-3","volume":"19","author":"A Sarathi","year":"2019","unstructured":"Sarathi A, Palaniappan A. Novel significant stage-specific differentially expressed genes in hepatocellular carcinoma. BMC Cancer. 2019;19(1):1\u201322.","journal-title":"BMC Cancer"},{"issue":"9","key":"5230_CR33","first-page":"3858","volume":"42","author":"H Nakabayashi","year":"1982","unstructured":"Nakabayashi H, et al. Growth of human hepatoma cell lines with differentiated functions in chemically defined medium. Cancer Res. 1982;42(9):3858\u201363.","journal-title":"Cancer Res"},{"issue":"2","key":"5230_CR34","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1111\/iep.12269","volume":"99","author":"EC Filipe","year":"2018","unstructured":"Filipe EC, Chitty JL, Cox TR. Charting the unexplored extracellular matrix in cancer. Int J Exp Pathol. 2018;99(2):58\u201376.","journal-title":"Int J Exp Pathol"},{"issue":"2","key":"5230_CR35","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1242\/dmm.004077","volume":"4","author":"TR Cox","year":"2011","unstructured":"Cox TR, Erler JT. Remodeling and homeostasis of the extracellular matrix: implications for fibrotic diseases and cancer. Dis Models Mech. 2011;4(2):165\u201378.","journal-title":"Dis Models Mech"},{"issue":"1","key":"5230_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-019-42604-0","volume":"9","author":"M Urbischek","year":"2019","unstructured":"Urbischek M, et al. Organoid culture media formulated with growth factors of defined cellular activity. Sci Rep. 2019;9(1):1\u201311.","journal-title":"Sci Rep"},{"issue":"1","key":"5230_CR37","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1021\/acsomega.1c05136","volume":"7","author":"H Poudel","year":"2021","unstructured":"Poudel H, et al. Synthetic matrices for Intestinal Organoid Culture: implications for Better Performance. ACS Omega. 2021;7(1):38\u201347.","journal-title":"ACS Omega"},{"key":"5230_CR38","unstructured":"Kleinman HK, Martin GR. Matrigel: basement membrane matrix with biological activity. Elsevier."},{"issue":"5","key":"5230_CR39","doi-asserted-by":"publisher","first-page":"e327","DOI":"10.1016\/j.jormas.2021.12.006","volume":"123","author":"IQ Guti\u00e9rrez","year":"2022","unstructured":"Guti\u00e9rrez IQ, S\u00e1bado-Bund\u00f3 H, Gay-Escoda C. Intraarticular injections of platelet rich plasma and plasma rich in growth factors with arthrocenthesis or arthroscopy in the treatment of temporomandibular joint disorders: a systematic review. J Stomatology Oral Maxillofacial Surg. 2022;123(5):e327\u201335.","journal-title":"J Stomatology Oral Maxillofacial Surg"},{"key":"5230_CR40","doi-asserted-by":"crossref","unstructured":"Guti\u00e9rrez IQ, S\u00e1bado-Bund\u00f3 H, Gay-Escoda C. Intraarticular injections of platelet rich plasma and plasma rich in growth factors with arthrocenthesis or arthroscopy in the treatment of temporomandibular joint disorders: a systematic review. Journal of Stomatology, Oral and Maxillofacial Surgery; 2021.","DOI":"10.1016\/j.jormas.2021.12.006"},{"issue":"9","key":"5230_CR41","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1016\/j.ijom.2011.04.009","volume":"40","author":"M Del Fabbro","year":"2011","unstructured":"Del Fabbro M, Bortolin M, Taschieri S. Is autologous platelet concentrate beneficial for post-extraction socket healing? A systematic review. Int J Oral Maxillofac Surg. 2011;40(9):891\u2013900.","journal-title":"Int J Oral Maxillofac Surg"},{"issue":"10","key":"5230_CR42","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.3390\/ph14101041","volume":"14","author":"A Zoltowska","year":"2021","unstructured":"Zoltowska A, et al. Plasma rich in growth factors in the treatment of endodontic periapical lesions in adult patients: a narrative review. Pharmaceuticals. 2021;14(10):1041.","journal-title":"Pharmaceuticals"},{"key":"5230_CR43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/scrt277","volume":"4","author":"P Van Pham","year":"2013","unstructured":"Van Pham P, et al. Activated platelet-rich plasma improves adipose-derived stem cell transplantation efficiency in injured articular cartilage. Stem Cell Res Ther. 2013;4:1\u201311.","journal-title":"Stem Cell Res Ther"},{"issue":"29","key":"5230_CR44","doi-asserted-by":"publisher","first-page":"7008","DOI":"10.1016\/j.biomaterials.2012.06.058","volume":"33","author":"X Xie","year":"2012","unstructured":"Xie X, et al. Comparative evaluation of MSCs from bone marrow and adipose tissue seeded in PRP-derived scaffold for cartilage regeneration. Biomaterials. 2012;33(29):7008\u201318.","journal-title":"Biomaterials"},{"issue":"10","key":"5230_CR45","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1016\/j.arthro.2013.07.259","volume":"29","author":"M Petrera","year":"2013","unstructured":"Petrera M, et al. Supplementation with platelet-rich plasma improves the in vitro formation of tissue-engineered cartilage with enhanced mechanical properties. Arthroscopy: J Arthroscopic Relat Surg. 2013;29(10):1685\u201392.","journal-title":"Arthroscopy: J Arthroscopic Relat Surg"},{"issue":"1","key":"5230_CR46","doi-asserted-by":"publisher","first-page":"5","DOI":"10.7603\/s40730-014-0005-6","volume":"1","author":"G Ra Hara","year":"2014","unstructured":"Ra Hara G, Basu T. Platelet-rich plasma in regenerative medicine. Biomedical Res Therapy. 2014;1(1):5.","journal-title":"Biomedical Res Therapy"},{"issue":"4","key":"5230_CR47","doi-asserted-by":"publisher","first-page":"189","DOI":"10.4103\/0974-2077.150734","volume":"7","author":"R Dhurat","year":"2014","unstructured":"Dhurat R, Sukesh MS. Principles and methods of preparation of platelet-rich plasma: a review and author\u2019s perspective. J Cutan Aesthetic Surg. 2014;7(4):189\u201397.","journal-title":"J Cutan Aesthetic Surg"},{"issue":"Suppl 1","key":"5230_CR48","doi-asserted-by":"publisher","first-page":"S12","DOI":"10.4103\/idoj.idoj_269_21","volume":"12","author":"S Dashore","year":"2021","unstructured":"Dashore S, et al. Preparation of platelet-rich plasma: National IADVL PRP taskforce recommendations. Indian Dermatology Online J. 2021;12(Suppl 1):S12\u201323.","journal-title":"Indian Dermatology Online J"},{"issue":"1","key":"5230_CR49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40729-017-0081-7","volume":"3","author":"K Isobe","year":"2017","unstructured":"Isobe K, et al. Mechanical and degradation properties of advanced platelet-rich fibrin (A-PRF), concentrated growth factors (CGF), and platelet-poor plasma-derived fibrin (PPTF). Int J Implant Dentistry. 2017;3(1):1\u20136.","journal-title":"Int J Implant Dentistry"},{"key":"5230_CR50","doi-asserted-by":"publisher","first-page":"4","DOI":"10.3389\/fbioe.2018.00004","volume":"6","author":"Y Kitamura","year":"2018","unstructured":"Kitamura Y, et al. Platelet counts in insoluble platelet-rich fibrin clots: a direct method for accurate determination. Front Bioeng Biotechnol. 2018;6:4.","journal-title":"Front Bioeng Biotechnol"},{"issue":"4","key":"5230_CR51","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1007\/s12663-015-0768-3","volume":"14","author":"S Nishimoto","year":"2015","unstructured":"Nishimoto S, et al. Growth factor measurement and histological analysis in platelet rich fibrin: a pilot study. J Oral Maxillofac Surg. 2015;14(4):907\u201313.","journal-title":"J Oral Maxillofac Surg"},{"issue":"4","key":"5230_CR52","doi-asserted-by":"publisher","first-page":"a022145","DOI":"10.1101\/cshperspect.a022145","volume":"9","author":"Y Zhang","year":"2017","unstructured":"Zhang Y, Alexander PB, Wang X-F. TGF-\u03b2 family signaling in the control of cell proliferation and survival. Cold Spring Harb Perspect Biol. 2017;9(4):a022145.","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"3","key":"5230_CR53","doi-asserted-by":"publisher","first-page":"534","DOI":"10.3892\/ijmm.2013.1606","volume":"33","author":"J Yokota","year":"2014","unstructured":"Yokota J, et al. PDGF-induced PI3K-mediated signaling enhances the TGF\u2013\u03b2\u2013induced osteogenic differentiation of human mesenchymal stem cells in a TGF-\u03b2-activated MEK-dependent manner. Int J Mol Med. 2014;33(3):534\u201342.","journal-title":"Int J Mol Med"},{"issue":"2","key":"5230_CR54","first-page":"295","volume":"112","author":"F Ng","year":"2008","unstructured":"Ng F, et al. PDGF, TGF-\u03b2, and FGF signaling is important for differentiation and growth of mesenchymal stem cells (MSCs): transcriptional profiling can identify markers and signaling pathways important in differentiation of MSCs into adipogenic, chondrogenic, and osteogenic lineages. Blood J Am Soc Hematol. 2008;112(2):295\u2013307.","journal-title":"Blood J Am Soc Hematol"},{"key":"5230_CR55","doi-asserted-by":"publisher","first-page":"83","DOI":"10.2147\/HP.S93413","volume":"3","author":"B Muz","year":"2015","unstructured":"Muz B, et al. The role of hypoxia in cancer progression, angiogenesis, metastasis, and resistance to therapy. Hypoxia. 2015;3:83.","journal-title":"Hypoxia"},{"issue":"1","key":"5230_CR56","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13058-016-0740-2","volume":"18","author":"KM Bussard","year":"2016","unstructured":"Bussard KM, et al. Tumor-associated stromal cells as key contributors to the tumor microenvironment. Breast Cancer Res. 2016;18(1):1\u201311.","journal-title":"Breast Cancer Res"},{"key":"5230_CR57","doi-asserted-by":"crossref","unstructured":"Yang D et al. Role of endothelial cells in tumor microenvironment. Clin Translational Med, 2021. 11(6).","DOI":"10.1002\/ctm2.450"},{"issue":"14","key":"5230_CR58","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.7150\/ijbs.25720","volume":"14","author":"S Guo","year":"2018","unstructured":"Guo S, Deng C-X. Effect of stromal cells in tumor microenvironment on metastasis initiation. Int J Biol Sci. 2018;14(14):2083.","journal-title":"Int J Biol Sci"},{"issue":"3","key":"5230_CR59","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1152\/physrev.00038.2010","volume":"91","author":"S Goel","year":"2011","unstructured":"Goel S, et al. Normalization of the vasculature for treatment of cancer and other diseases. Physiol Rev. 2011;91(3):1071\u2013121.","journal-title":"Physiol Rev"},{"issue":"1","key":"5230_CR60","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1002\/stem.559","volume":"29","author":"AH Klopp","year":"2011","unstructured":"Klopp AH, et al. Concise review: dissecting a discrepancy in the literature: do mesenchymal stem cells support or suppress tumor growth? Stem Cells. 2011;29(1):11\u20139.","journal-title":"Stem Cells"},{"issue":"10","key":"5230_CR61","doi-asserted-by":"publisher","first-page":"2614","DOI":"10.1002\/stem.187","volume":"27","author":"S Kidd","year":"2009","unstructured":"Kidd S, et al. Direct evidence of mesenchymal stem cell tropism for tumor and wounding microenvironments using in vivo bioluminescent imaging. Stem Cells. 2009;27(10):2614\u201323.","journal-title":"Stem Cells"},{"issue":"8","key":"5230_CR62","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1038\/s41556-019-0359-5","volume":"21","author":"L Sun","year":"2019","unstructured":"Sun L, et al. Modelling liver cancer initiation with organoids derived from directly reprogrammed human hepatocytes. Nat Cell Biol. 2019;21(8):1015\u201326.","journal-title":"Nat Cell Biol"},{"key":"5230_CR63","doi-asserted-by":"crossref","unstructured":"O Oz, et al. 3d organoid modelling of hepatoblast-like and mesenchymal-like hepatocellular carcinoma cell lines. Hepatoma Res. 2021;7:60.","DOI":"10.20517\/2394-5079.2021.43"},{"issue":"1","key":"5230_CR64","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1747-1028-1-32","volume":"1","author":"K Yang","year":"2006","unstructured":"Yang K, Hitomi M, Stacey DW. Variations in cyclin D1 levels through the cell cycle determine the proliferative fate of a cell. Cell Div. 2006;1(1):1\u20138.","journal-title":"Cell Div"},{"issue":"3","key":"5230_CR65","doi-asserted-by":"publisher","first-page":"2400","DOI":"10.1128\/MCB.19.3.2400","volume":"19","author":"R Yang","year":"1999","unstructured":"Yang R, et al. Functions of cyclin A1 in the cell cycle and its interactions with transcription factor E2F-1 and the rb family of proteins. Mol Cell Biol. 1999;19(3):2400\u20137.","journal-title":"Mol Cell Biol"},{"issue":"1","key":"5230_CR66","doi-asserted-by":"publisher","first-page":"57","DOI":"10.4161\/cc.11.1.18775","volume":"11","author":"KT Siu","year":"2012","unstructured":"Siu KT, Rosner MR, Minella AC. An integrated view of cyclin E function and regulation. Cell Cycle. 2012;11(1):57\u201364.","journal-title":"Cell Cycle"},{"issue":"4","key":"5230_CR67","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.devcel.2010.02.013","volume":"18","author":"O Gavet","year":"2010","unstructured":"Gavet O, Pines J. Progressive activation of CyclinB1-Cdk1 coordinates entry to mitosis. Dev Cell. 2010;18(4):533\u201343.","journal-title":"Dev Cell"},{"issue":"1","key":"5230_CR68","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/cdd.2017.169","volume":"25","author":"BJ Aubrey","year":"2018","unstructured":"Aubrey BJ, et al. How does p53 induce apoptosis and how does this relate to p53-mediated tumour suppression? Cell Death Differ. 2018;25(1):104\u201313.","journal-title":"Cell Death Differ"},{"issue":"3","key":"5230_CR69","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1083\/jcb.200202130","volume":"158","author":"SP Cregan","year":"2002","unstructured":"Cregan SP, et al. Apoptosis-inducing factor is involved in the regulation of caspase-independent neuronal cell death. J Cell Biol. 2002;158(3):507\u201317.","journal-title":"J Cell Biol"},{"issue":"3","key":"5230_CR70","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/j.ygyno.2005.02.018","volume":"97","author":"S B\u00e9langer","year":"2005","unstructured":"B\u00e9langer S, et al. Bcl-2 decreases cell proliferation and promotes accumulation of cells in S phase without affecting the rate of apoptosis in human ovarian carcinoma cells. Gynecol Oncol. 2005;97(3):796\u2013806.","journal-title":"Gynecol Oncol"},{"issue":"8","key":"5230_CR71","doi-asserted-by":"publisher","first-page":"3364","DOI":"10.1128\/MCB.25.8.3364-3387.2005","volume":"25","author":"BC Dash","year":"2005","unstructured":"Dash BC, El-Deiry WS. Phosphorylation of p21 in G2\/M promotes cyclin B-Cdc2 kinase activity. Mol Cell Biol. 2005;25(8):3364\u201387.","journal-title":"Mol Cell Biol"},{"issue":"1","key":"5230_CR72","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-020-79139-8","volume":"11","author":"W Wang","year":"2021","unstructured":"Wang W, et al. The clinical significance of microvascular invasion in the surgical planning and postoperative sequential treatment in hepatocellular carcinoma. Sci Rep. 2021;11(1):1\u201310.","journal-title":"Sci Rep"},{"issue":"14","key":"5230_CR73","doi-asserted-by":"publisher","first-page":"7255","DOI":"10.3390\/ijms22147255","volume":"22","author":"F Papaccio","year":"2021","unstructured":"Papaccio F, et al. Profiling cancer-associated fibroblasts in melanoma. Int J Mol Sci. 2021;22(14):7255.","journal-title":"Int J Mol Sci"},{"issue":"6","key":"5230_CR74","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1016\/j.cell.2012.03.048","volume":"149","author":"B Hu","year":"2012","unstructured":"Hu B, et al. Multifocal epithelial tumors and field cancerization from loss of mesenchymal CSL signaling. Cell. 2012;149(6):1207\u201320.","journal-title":"Cell"},{"key":"5230_CR75","doi-asserted-by":"crossref","unstructured":"Truong D et al. Breast cancer cell invasion into a three dimensional tumor-stroma microenvironment 2016. 6(1): pp. 1\u201318.","DOI":"10.1038\/srep34094"},{"key":"5230_CR76","doi-asserted-by":"crossref","unstructured":"Chabottaux V et al. Membrane-type 4 matrix metalloproteinase (MT4\u2010MMP) induces lung metastasis by alteration of primary breast tumour vascular architecture. 2009. 13(9b): p. 4002\u201313.","DOI":"10.1111\/j.1582-4934.2009.00764.x"},{"issue":"1","key":"5230_CR77","doi-asserted-by":"publisher","first-page":"5120","DOI":"10.1038\/s41467-020-18794-x","volume":"11","author":"J Winkler","year":"2020","unstructured":"Winkler J, et al. Concepts of extracellular matrix remodelling in tumour progression and metastasis. Nat Commun. 2020;11(1):5120.","journal-title":"Nat Commun"},{"issue":"4","key":"5230_CR78","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1083\/jcb.201102147","volume":"196","author":"P Lu","year":"2012","unstructured":"Lu P, Weaver VM, Werb Z. The extracellular matrix: a dynamic niche in cancer progression. J Cell Biol. 2012;196(4):395\u2013406.","journal-title":"J Cell Biol"},{"key":"5230_CR79","doi-asserted-by":"crossref","unstructured":"Yuen MF et al. Expression of c-Myc, c\u2010Fos, and c\u2010jun in hepatocellular carcinoma. 2001. 91(1): p. 106\u201312.","DOI":"10.1002\/1097-0142(20010101)91:1<106::AID-CNCR14>3.0.CO;2-2"},{"issue":"8","key":"5230_CR80","first-page":"1175","volume":"12","author":"L Zhou","year":"2006","unstructured":"Zhou L, Liu J. J.W.j.o.g.W. Luo. Serum Tumor Markers Detect Hepatocellular Carcinoma. 2006;12(8):1175.","journal-title":"Serum Tumor Markers Detect Hepatocellular Carcinoma"},{"key":"5230_CR81","doi-asserted-by":"crossref","unstructured":"Teng K et al. KIFC1 is activated by TCF-4 and promotes hepatocellular carcinoma pathogenesis by regulating HMGA1 transcriptional activity. 2019. 38(1): p. 1\u201320.","DOI":"10.1186\/s13046-019-1331-8"},{"key":"5230_CR82","doi-asserted-by":"crossref","unstructured":"Bai Y et al. The diagnostic and prognostic role of RhoA in hepatocellular carcinoma. 2019. 11(14): p. 5158.","DOI":"10.18632\/aging.102110"},{"key":"5230_CR83","doi-asserted-by":"crossref","unstructured":"Martinez-Quetglas I et al. IGF2 is up-regulated by epigenetic mechanisms in hepatocellular carcinomas and is an actionable oncogene product in experimental models. 2016. 151(6): p. 1192\u2013205.","DOI":"10.1053\/j.gastro.2016.09.001"},{"key":"5230_CR84","doi-asserted-by":"crossref","unstructured":"Debruyne EN. and J.R.J.C.c.a. Delanghe, Diagnosing and monitoring hepatocellular carcinoma with alpha-fetoprotein: new aspects and applications. 2008. 395(1\u20132): p. 19\u201326.","DOI":"10.1016\/j.cca.2008.05.010"},{"key":"5230_CR85","doi-asserted-by":"crossref","unstructured":"Hoffmann B et al. The initial engraftment of tumor cells is critical for the future growth pattern: a mathematical study based on simulations and animal experiments. 2020. 20(1): p. 1\u201314.","DOI":"10.1186\/s12885-020-07015-9"},{"key":"5230_CR86","doi-asserted-by":"crossref","unstructured":"Sarathi A. and A.J.B.c. Palaniappan, Novel significant stage-specific differentially expressed genes in hepatocellular carcinoma. 2019. 19(1): p. 1\u201322.","DOI":"10.1186\/s12885-019-5838-3"},{"issue":"9","key":"5230_CR87","first-page":"3858","volume":"42","author":"H Nakabayashi","year":"1982","unstructured":"Nakabayashi H, et al. Growth Hum Hepatoma cell Lines Differentiated Funct Chemically Defined Medium. 1982;42(9):3858\u201363.","journal-title":"Growth Hum Hepatoma cell Lines Differentiated Funct Chemically Defined Medium"},{"key":"5230_CR88","doi-asserted-by":"crossref","unstructured":"Shimono Y, et al. Organoid culture of human cancer stem cells, in Organoids. Springer; 2016. pp. 23\u201331.","DOI":"10.1007\/7651_2016_13"},{"issue":"22","key":"5230_CR89","doi-asserted-by":"publisher","first-page":"7856","DOI":"10.1039\/D0CS00379D","volume":"49","author":"J Han","year":"2020","unstructured":"Han J, et al. Cancer stem cell-targeted bio-imaging and chemotherapeutic perspective. Chem Soc Rev. 2020;49(22):7856\u201378.","journal-title":"Chem Soc Rev"},{"issue":"3","key":"5230_CR90","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1053\/j.gastro.2008.12.004","volume":"136","author":"T Yamashita","year":"2009","unstructured":"Yamashita T, et al. EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem\/progenitor cell features. Gastroenterology. 2009;136(3):1012\u201324.","journal-title":"Gastroenterology"},{"issue":"8","key":"5230_CR91","doi-asserted-by":"publisher","first-page":"2185","DOI":"10.1002\/1878-0261.12916","volume":"15","author":"M Karabicici","year":"2021","unstructured":"Karabicici M, et al. Doxorubicin-induced senescence promotes stemness and tumorigenicity in EpCAM\u2013\/CD133\u2009\u2013\u2009nonstem cell population in hepatocellular carcinoma cell line, HuH\u20107. Mol Oncol. 2021;15(8):2185\u2013202.","journal-title":"Mol Oncol"},{"issue":"1","key":"5230_CR92","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2164-4-11","volume":"4","author":"V Nygaard","year":"2003","unstructured":"Nygaard V, et al. Effects of mRNA amplification on gene expression ratios in cDNA experiments estimated by analysis of variance. BMC Genomics. 2003;4(1):1\u201313.","journal-title":"BMC Genomics"},{"issue":"1","key":"5230_CR93","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1002\/cam4.55","volume":"2","author":"A Osaki","year":"2013","unstructured":"Osaki A, et al. A safe and effective dose of cisplatin in hepatic arterial infusion chemotherapy for hepatocellular carcinoma. Cancer Med. 2013;2(1):86\u201398.","journal-title":"Cancer Med"},{"key":"5230_CR94","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1023\/A:1013156407224","volume":"20","author":"LA Hazlehurst","year":"2001","unstructured":"Hazlehurst LA, Dalton WS. Mechanisms associated with cell adhesion mediated drug resistance (CAM-DR) in hematopoietic malignancies. Cancer Metastasis Rev. 2001;20:43\u201350.","journal-title":"Cancer Metastasis Rev"},{"issue":"8","key":"5230_CR95","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.3390\/cancers12082063","volume":"12","author":"S Raghavan","year":"2020","unstructured":"Raghavan S, et al. Carcinoma-associated mesenchymal stem cells promote chemoresistance in ovarian cancer stem cells via PDGF signaling. Cancers. 2020;12(8):2063.","journal-title":"Cancers"},{"issue":"11","key":"5230_CR96","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1101\/gad.193565.112","volume":"26","author":"Y Kim","year":"2012","unstructured":"Kim Y, et al. Platelet-derived growth factor receptors differentially inform intertumoral and intratumoral heterogeneity. Genes Dev. 2012;26(11):1247\u201362.","journal-title":"Genes Dev"},{"issue":"9","key":"5230_CR97","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1111\/jphp.13136","volume":"71","author":"Y Meng","year":"2019","unstructured":"Meng Y, et al. Basic fibroblast growth factor signalling regulates cancer stem cells in lung cancer A549 cells. J Pharm Pharmacol. 2019;71(9):1412\u201320.","journal-title":"J Pharm Pharmacol"},{"issue":"1","key":"5230_CR98","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-019-53907-7","volume":"9","author":"J Otte","year":"2019","unstructured":"Otte J, et al. FGF signalling in the self-renewal of colon cancer organoids. Sci Rep. 2019;9(1):1\u201310.","journal-title":"Sci Rep"},{"issue":"1","key":"5230_CR99","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-020-77238-0","volume":"10","author":"Y Tang","year":"2020","unstructured":"Tang Y, et al. Autologous culture method improves retention of tumors\u2019 native properties. Sci Rep. 2020;10(1):1\u201310.","journal-title":"Sci Rep"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-024-05230-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-024-05230-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-024-05230-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T18:02:18Z","timestamp":1716314538000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-024-05230-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,21]]},"references-count":99,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["5230"],"URL":"https:\/\/doi.org\/10.1186\/s12967-024-05230-7","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,21]]},"assertion":[{"value":"22 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The protocol for obtaining serum samples was approved by the IRB from the Faculty of Medicine Cairo University, Cairo University - Faculty of Medicine - Research Ethics Committee, protocol approval number: N-56-2020, and the National Liver Institute Menoufia University, NLI IRB 00003413 FWA0000227, protocol approval number: 665 00140\/208.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"487"}}